Finanzen von Turnstone Biologics Corp (TSBX)TSBXTurnstone Biologics Corp

Evaluating the bottom line, Turnstone Biologics Corp maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -126.71%, provide a clear picture of how effectively TSBX converts its operational activities into shareholder value.

In the context of the broader market, TSBX competes directly with industry leaders such as ADVB and TRAW. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, TSBX's gross margin of N/A stands against ADVB's N/A and TRAW's N/A. Such benchmarking helps identify whether Turnstone Biologics Corp is trading at a premium or discount relative to its financial performance.